CCLD trades 45.6% below Wall Street's consensus target of $3.13.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CCLD achieves its forward estimates and maintains a stable P/E multiple of 12.3x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, CareCloud, Inc. (CCLD) has a Wall Street consensus price target of $3.13, based on estimates from 7 covering analysts. With the stock currently trading at $2.15, this represents a potential upside of +45.6%. The company has a market capitalization of $91M.
Analyst price targets range from a low of $3.00 to a high of $3.25, representing a 8% spread in expectations. The median target of $3.13 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CCLD trades at a trailing P/E of 21.5x and forward P/E of 12.3x. Analysts expect EPS to grow -23.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HCATHealth Catalyst, Inc. | $140M | $1.90 | $2.13 | +12.1% | Buy | 45.3x | 22 |
PHRPhreesia, Inc. | $622M | $10.07 | $13.57 | +34.8% | Buy | 25.1x | 25 |
DOCSDoximity, Inc. | $3.9B | $20.88 | $29.47 | +41.1% | Hold | 14.6x | 23 |
VEEVVeeva Systems Inc. | $27.8B | $171.36 | $235.38 | +37.4% | Buy | 18.9x | 43 |
CLOVClover Health Investments, Corp. | $2.8B | $5.41 | $4.47 | -17.4% | Hold | 139.8x | 9 |
TDOCTeladoc Health, Inc. | $1.5B | $8.39 | $7.40 | -11.8% | Hold | — | 42 |
AMWLAmerican Well Corporation | $154M | $9.19 | $6.33 | -31.1% | Hold | — | 15 |
OPRXOptimizeRx Corporation | $96M | $5.12 | $17.00 | +232.0% | Buy | 5.4x | 15 |
INVAInnoviva, Inc. | $1.7B | $23.57 | $37.00 | +57.0% | Buy | 6.6x | 10 |
GDRXGoodRx Holdings, Inc. | $971M | $2.80 | $3.08 | +10.0% | Hold | 9.1x | 24 |
Quick answers to the most common questions about buying CCLD stock.
The consensus Wall Street price target for CCLD is $3.13, representing 45.6% upside from the current price of $2.15. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CCLD has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $3.13 implies 45.6% upside from current levels.
With a forward P/E of 12.2857x, CCLD trades at a relatively low valuation. The consensus target of $3.13 implies 45.6% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $3.25 for CCLD, while the most conservative target is $3. The consensus of $3.13 represents the median expectation. These targets typically reflect 12-month expectations.
CCLD is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CCLD stock forecast based on 7 Wall Street analysts shows a consensus price target of $3.13, with estimates ranging from $3 (bear case) to $3.25 (bull case). The median consensus rating is "Buy".
CCLD trades at a forward P/E ratio of 12.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 21.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on CCLD, with a "Buy" consensus rating and $3.13 price target (45.6% upside). 6 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CCLD analyst price targets range from $3 to $3.25, a 8% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3.13 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.